151 related articles for article (PubMed ID: 21867939)
1. Second-wave protease inhibitors: choosing an heir.
Ciesek S; von Hahn T; Manns MP
Clin Liver Dis; 2011 Aug; 15(3):597-609. PubMed ID: 21867939
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients.
Martel-Laferrière V; Bichoupan K; Dieterich DT
J Clin Gastroenterol; 2014 Feb; 48(2):106-12. PubMed ID: 24172182
[TBL] [Abstract][Full Text] [Related]
3. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
Tornai I
Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
[TBL] [Abstract][Full Text] [Related]
4. HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R; Halfon P; Marcellin P; Asselah T
Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
[TBL] [Abstract][Full Text] [Related]
5. [New antiviral agents against hepatitis C in clinical trials. Hope for a cure--but resistance problems must be overcomed].
Lennerstrand J; Bondeson K; Bergqvist A; Blomberg J; Oberg B
Lakartidningen; 2009 Nov 25-Dec 1; 106(48):3254-6, 3258, 3260. PubMed ID: 20101837
[No Abstract] [Full Text] [Related]
6. Antiviral treatment of hepatitis C.
Feeney ER; Chung RT
BMJ; 2014 Jul; 348():g3308. PubMed ID: 25002352
[TBL] [Abstract][Full Text] [Related]
7. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
[TBL] [Abstract][Full Text] [Related]
8. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
Venkatraman S
Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis C virus infection in the near future.
Cheinquer H
Ann Hepatol; 2013; 12(6):854-9. PubMed ID: 24114813
[No Abstract] [Full Text] [Related]
10. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Jensen DM; Asselah T; Dieterich D; Foster GR; Sulkowski MS; Zeuzem S; Mantry P; Yoshida EM; Moreno C; Ouzan D; Wright M; Morano LE; Buynak R; Bourlière M; Hassanein T; Nishiguchi S; Kao JH; Omata M; Paik SW; Wong DK; Tam E; Kaita K; Feinman SV; Stern JO; Scherer J; Quinson AM; Voss F; Gallivan JP; Böcher WO; Ferenci P
Ann Hepatol; 2016; 15(3):333-49. PubMed ID: 27049487
[TBL] [Abstract][Full Text] [Related]
11. Faldaprevir for the treatment of genotype-1 hepatitis C virus.
Agarwal K; Barnabas A
Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):277-88. PubMed ID: 25633983
[TBL] [Abstract][Full Text] [Related]
12. Faldaprevir for the treatment of hepatitis C.
Kanda T; Yokosuka O; Omata M
Int J Mol Sci; 2015 Mar; 16(3):4985-96. PubMed ID: 25749475
[TBL] [Abstract][Full Text] [Related]
13. Simeprevir for the treatment of chronic hepatitis C.
You DM; Pockros PJ
Expert Opin Pharmacother; 2013 Dec; 14(18):2581-9. PubMed ID: 24138198
[TBL] [Abstract][Full Text] [Related]
14. Simeprevir approved for hepatitis C virus infection.
Traynor K
Am J Health Syst Pharm; 2014 Jan; 71(1):6. PubMed ID: 24352170
[No Abstract] [Full Text] [Related]
15. Boceprevir, an NS3 protease inhibitor of HCV.
Berman K; Kwo PY
Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
[TBL] [Abstract][Full Text] [Related]
16. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
Tsantrizos YS
Curr Opin Investig Drugs; 2009 Aug; 10(8):871-81. PubMed ID: 19649931
[TBL] [Abstract][Full Text] [Related]
17. Simeprevir: a macrocyclic HCV protease inhibitor.
Talwani R; Heil EL; Gilliam BL; Temesgen Z
Drugs Today (Barc); 2013 Dec; 49(12):769-79. PubMed ID: 24524095
[TBL] [Abstract][Full Text] [Related]
18. Protease inhibitors: silver bullets for chronic hepatitis C infection?
Alkhouri N; Zein NN
Cleve Clin J Med; 2012 Mar; 79(3):213-22. PubMed ID: 22383557
[TBL] [Abstract][Full Text] [Related]
19. Simeprevir: first global approval.
Vaidya A; Perry CM
Drugs; 2013 Dec; 73(18):2093-106. PubMed ID: 24293133
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C management in post-transplant patients.
Hilgenfeldt E; Firpi RJ
Minerva Gastroenterol Dietol; 2015 Mar; 61(1):21-9. PubMed ID: 25390286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
